DSpace Repository

The effects of dydrogesterone treatment on first- trimester aneuploidy screening markers and nuchal translucency in women with threatened miscarriage

Show simple item record

dc.contributor.author Yildiz, Elif
dc.contributor.author Timur, Burcu
dc.date.accessioned 2024-03-15T08:31:40Z
dc.date.available 2024-03-15T08:31:40Z
dc.date.issued 2023
dc.identifier.citation Yildiz, E., Timur, B. (2023). The effects of dydrogesterone treatment on first- trimester aneuploidy screening markers and nuchal translucency in women with threatened miscarriage. Turk. J. Obstet. Gynecol., 20(1), 16-21. https://doi.org/10.4274/tjod.galenos.2023.97493 en_US
dc.identifier.issn 2149-9322
dc.identifier.issn 2149-9330
dc.identifier.uri http://dx.doi.org/10.4274/tjod.galenos.2023.97493
dc.identifier.uri https://www.webofscience.com/wos/woscc/full-record/WOS:000954025200005
dc.identifier.uri http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4241
dc.description WoS Categories: Obstetrics & Gynecology en_US
dc.description Web of Science Index: Emerging Sources Citation Index (ESCI) en_US
dc.description Research Areas: Obstetrics & Gynecology en_US
dc.description.abstract Objective: To evaluate the effects of dydrogesterone treatment on first-trimester aneuploidy screening markers and nuchal translucency (NT) in women with threatened miscarriage.Materials and Methods: This study is an prospective case-control study. One hundred seven pregnant women who applied for the first-trimester screening test at 11-14th weeks of gestation were included in the study. The study group consisted of 53 pregnant women using oral dydrogesterone due to the threat of miscarriage for at least 2 weeks and without vaginal bleeding for the last 72 h at the time of enrollment. The control group was composed of 54 healty pregnant women. Fetal Crown-rump length (CRL), NT, pregnancy-associated plasma protein-A (PAP-A) level, and free beta-human chorionic gonadotropin (free B-hCG) levels of the patients were measured.Results: One hundred seven patients included in the study, 54 (50.46%) were in the control group, and 53 (49.54%) were in the study group using dydrogesterone. Age, body mass index, gravida, parity and abortion numbers, gestational weeks, and CRL values of the two groups were congruent. In the comparison-free B-hCG, PAPP-A and NT values of both groups, no statistically significant difference was found between the two groups in terms of first-trimester test results and NT (p<0.05).Conclusion: The use of dydrogesterone in first-trimester pregnancies does not affect first-trimester screening tests and nuchal translucency. en_US
dc.language.iso eng en_US
dc.publisher GALENOS PUBL HOUSE-ISTANBUL en_US
dc.relation.isversionof 10.4274/tjod.galenos.2023.97493 en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Dydrogesterone, nuchal translucency, threatened miscarriage, prenatal screening tests en_US
dc.subject PROGESTERONE THERAPY, EARLY-PREGNANCY, ULTRASOUND, DIAGNOSIS en_US
dc.title The effects of dydrogesterone treatment on first- trimester aneuploidy screening markers and nuchal translucency in women with threatened miscarriage en_US
dc.type article en_US
dc.relation.journal TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY en_US
dc.contributor.department Ordu Üniversitesi en_US
dc.contributor.authorID 0000-0001-8396-5542 en_US
dc.contributor.authorID 0000-0001-8769-5949 en_US
dc.identifier.volume 20 en_US
dc.identifier.issue 1 en_US
dc.identifier.startpage 16 en_US
dc.identifier.endpage 21 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account